These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16807423)

  • 1. Fondaparinux versus enoxaparin in acute coronary syndromes.
    Majure DT; Aberegg SK
    N Engl J Med; 2006 Jun; 354(26):2829; author reply 2830. PubMed ID: 16807423
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
    Alexander JH; Harrington RA
    Curr Cardiol Rep; 2006 Jul; 8(4):279-81. PubMed ID: 16883666
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for patients with acute coronary syndromes--new opportunities.
    Gibbons RJ; Fuster V
    N Engl J Med; 2006 Apr; 354(14):1524-7. PubMed ID: 16537664
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.
    Cohen M
    J Thromb Thrombolysis; 2001 Apr; 11(2):171-4. PubMed ID: 11406733
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Fox KA; Bassand JP; Mehta SR; Wallentin L; Theroux P; Piegas LS; Valentin V; Moccetti T; Chrolavicius S; Afzal R; Yusuf S;
    Ann Intern Med; 2007 Sep; 147(5):304-10. PubMed ID: 17785485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction.
    Sleight P; Eikelboom JW; Bassand JP
    N Engl J Med; 2006 Jun; 354(26):2830-1; author reply 2831-2. PubMed ID: 16810777
    [No Abstract]   [Full Text] [Related]  

  • 11. Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
    Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2012 May; 105(5):259-61. PubMed ID: 22709466
    [No Abstract]   [Full Text] [Related]  

  • 12. Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
    Moliterno DJ
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):191-2. PubMed ID: 21290553
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
    Coons JC; Battistone S
    Ann Pharmacother; 2008 Jul; 42(7):989-1001. PubMed ID: 18577763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.